Top Tech Companies (139)
Atlas Biomed is a personalized health company applying the latest genetic technologies to inspire consumers into a positive lifestyle change, and lead them into a healthier future.
ENBIOSIS Biosciences reaches deep into your inner world with microbiome analysis and offers you the key for a sustainable and healthy life
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love to innovate and develop exciting technologies, and we offer competitive salaries and progressive benefits. But it’s our culture - of Care, Collaboration and Courage - that really sets us apart. Through a spirit of ownership and can-do attitude, we work together to win.. We’re a company of people who care about each other, about our customers and their patients, and about our communities. Together, we fulfill our shared purpose of Life Unlimited.
We believe that everyone - irrespective of who they are or where they live - deserve medications that work
Isomorphic Labs is a new Alphabet company and commercial venture which aims to reimagine the entire drug discovery process from first principles with an AI-first approach, and, ultimately, to model and understand some of the fundamental mechanisms of life. Using computational advances, we’re working at the cutting edge in the new era of ‘digital biology’. By significantly increasing the pace of scientific research and efficacy of new medicines, we will be at the forefront of breakthroughs that will benefit millions of people.
More sustainable products, for everyday use Carbon chains are the backbones in most modern products, extracted from crude oil and converted into anything from materials to ingredients. Scindo is working towards a circular future, where your favourite products are sustainably manufactured from renewable or recycled feedstocks. We are developing cutting-edge enzyme systems to address two global challenges: the reliance on crude oil, and the global plastic waste crisis
We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and are maximizing the potential of our technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, we have fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate
Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. For more information on our company, please visit www.Exagen.com. For more information on AVISE testing services, please visit www.AviseTest.com. Read our Social Media Terms of Use here: http://bit.ly/smtou
Mytos automates one of the last highly manual processes in biotech - growing human cells. Our products help teams in drug development and cell therapy save time while increasing the reproducibility of their data. Mytos is backed by a fleet of leading investors including YCombinator. Our team is made up of brilliant engineers from Dyson, Formlabs and Cambridge Consultants and driven scientists who have worked in top labs including at Imperial College, University of Cambridge and UCL. We're hiring now- visit our website to see open positions
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases
Detecting brain diseases radically early using the way you speak
Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and clinical testing, to microbiome analysis, and support on formulation development and certification. (www.sequential.bio) Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, Corundum Systems Biology, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a multidisciplinary team of clinicians, translational neuroengineers, medtech industry professionals and experienced entrepreneurs focused on developing transformational therapy innovation for major unmet medical conditions. The Company was spun out from the University of Oxford in 2021 and is backed by Oxford Science Enterprises and 8VC
At AviadoBio our mission is to potentially transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
CN Bio is a leading organ-on-a-chip (OOC) company that enables researchers to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® suite of microphysiological systems, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Intestine/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment and function of their human counterparts in vitro. The approach provides a viable alternative to animal models where translatability to humans is predicted to be poor and for testing advanced drug modalities where human-specific targets and pathways are required. They generate physiologically relevant, human-translatable, mechanistic data that enables researchers to progress only the safest and most efficacious drugs into in vivo animal studies and be better prepared for clinical trials. Please follow us for regular updates. It starts here.
Inoviv uses a novel technology platform based on targeted proteomics to support pharmaceutical companies with biomarker test development.
Digistain ® - Leading digital transformation in cancer diagnostics - radically faster gold standard risk scoring analytics at a dramatically lower cost A Digital Solution To Cancer Grading And Prognosis approved by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), DIGISTAIN® is a patented risk profiling test for hormone receptor-positive breast cancer patients. Digistain’s easy-to-read report provides both physician and patient clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required. The MHRA approved DIGISTAIN technology is based on 15 years of research and development pioneered by respected cancer research scientists at Imperial College with Professor Chris Phillips of the Biomedical Optics Division and Cancer Research UK (CRUK) with Professor Sir Nicholas Wright of Barts Hospital London, Head of Histopathology at CRUK and ex-president of the Pathological Society of Great Britain
We are a pioneering healthcare company that aims to transform health through the power of genomics. The company was formed in 2014 by four world-leading statistical and human geneticists at the University of Oxford, including Professor Sir Peter Donnelly and Professor Gil McVean. We use large-scale genetic information to realise preventative medicine and improve drug discovery. We're a world-leader in genomic prevention: a paradigm-changing approach to sustainable healthcare which for the first time allows reliable, personalised estimates of risk for all the common diseases and cancers, well ahead of disease manifestation, allowing accurate and early interventions and tailored screening. Our proprietary algorithms and databases offer something no competitor can: the ability to accurately link minute variation across the entire genome to changes in thousands of biological measurements and disease outcomes, to generate population-level insights for healthcare systems, individual-level insights for clinicians about the risk of common diseases, and new understanding of disease processes. In August 2018, we announced a multi-year collaboration with Vertex to use human genetics and data science to advance discovery of precision medicines. We also have several pilot programmes in development within UK and US healthcare systems. Our team is a multi-disciplinary group focused on finding powerful and creative solutions for bringing subject-leading science to as wide an audience as possible, and, in doing so, offer the chance of transforming lives around the world. The workforce is highly qualified and consists of over 150 people, including genomic scientists, computational biologists, statisticians, software engineers, product developers, data scientists and commercial strategists. We are headquartered in Oxford, with offices in Cambridge (UK), London (UK), and Boston (US).
.png)
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family story and gain a new level of understanding about their lives. For 40 years, we’ve built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing their story.
Phycobloom is developing the next generation of algae for the future world.
